The United Kingdom and the United States have finalized a important trade agreement that will guarantee zero import taxes on UK drug products being sold in the US market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to boost funding on medicines through the NHS. This pledge ensures that tariffs on these crucial products will be held at nothing for a duration of three years.
This development comes after recent warnings to significantly raise duties on branded drug products, with figures floated reaching one hundred percent.
"This arrangement between the Britain bolsters the global environment for innovative medicines and brings long-overdue equity to U.S.–U.K. medicine commerce," an announcement noted.
Commercial Importance
Pharmaceuticals are one of the the United Kingdom's most significant goods shipped to the United States, which is easily the largest market for large companies like GSK and AstraZeneca.
Export figures show that in the year to the end of the third quarter, the UK sold pharmaceutical products totaling £11.1bn to the US. This amount made up nearly one-fifth of all goods exports in that period.
"This guarantee secures work, increases funding and paves the way for the UK to emerge as a worldwide center for medical research," a minister remarked.
Detailed NHS Changes
The agreement involves several key commitments from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new treatments to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a aim to double overall NHS spending on drugs from 0.3% of GDP to 0.6% over the next decade.
- Payback Limit: The percentage manufacturers must return to the NHS to control costs will be limited at fifteen percent. Previously, rebates were more than 20%.
Broader Context
The deal takes place against a ongoing tension between the drug companies and the UK government over medicine costs and approval rates.
The disagreement were exacerbated by assertions that American patients were charged a premium for the same drugs than people in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been pledged toward US facilities.
The Science Minister acknowledged that the NHS must invest a greater share on medicines, noting that its budget allocation on drugs had declined as a share of its total funding over the last ten years.
